Glucagonoma epidemiology and demographics

Revision as of 14:26, 17 November 2017 by Anthony Gallo (talk | contribs)
Jump to navigation Jump to search

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma epidemiology and demographics

CDC on Glucagonoma epidemiology and demographics

Glucagonoma epidemiology and demographics in the news

Blogs on Glucagonoma epidemiology and demographics

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

The incidence of glucagonoma is approximately 0.0005 per 100,000 individuals worldwide. Glucagonoma affects men and women equally. The median age of diagnosis is the fifth decade.

Epidemiology and Demographics

Incidence

Age

  • Patients typically present in their fifth decade with lesions mainly located in the tail of the pancreas, whereas patients with MEN I present at the younger age of 33 y.[4][5]

Gender

  • Glucagonoma affects men and women equally.

References

  1. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P; et al. (2012). "ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes". Neuroendocrinology. 95 (2): 98–119. doi:10.1159/000335591. PMC 3701449. PMID 22261919.
  2. Lévy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D; et al. (2004). "Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry". Gastroenterol Clin Biol. 28 (11): 1075–81. PMID 15657529.
  3. Rajesh V. Thakker, Paul J. Newey, Gerard V. Walls, John Bilezikian, Henning Dralle, Peter R. Ebeling, Shlomo Melmed, Akihiro Sakurai, Francesco Tonelli & Maria Luisa Brandi (2012). "Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)". The Journal of clinical endocrinology and metabolism. 97 (9): 2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327. Unknown parameter |month= ignored (help)
  4. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). "The glucagonoma syndrome. Clinical and pathologic features in 21 patients". Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.
  5. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). "The glucagonoma syndrome. Clinical and pathologic features in 21 patients". Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.

Template:WH Template:WS